Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.78 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.43 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31237486 | 1.00 | CES1 (0.78) | CES1ESR2BCHEACHECES2 | |
| SCHEMBL3580678 | 0.86 | CES1 (0.59) | CES1ESR2BCHEACHEPOLB | |
| SCHEMBL3584746 | 0.84 | CES1 (0.59) | CES1ESR2BCHEACHEPOLB | |
| SCHEMBL3584503 | 0.82 | CES1 (0.78) | CES1ESR2BCHEACHECES2 | |
| SCHEMBL3584662 | 0.78 | CES1 (0.53) | CES1ESR2BCHEACHEESR1 | |
| SCHEMBL3585903 | 0.77 | CES1 (0.48) | CES1ESR2BCHEACHECES2 | |
| SCHEMBL3585460 | 0.76 | CES1 (0.51) | CES1ESR2BCHEACHEPOLB | |
| SCHEMBL13286304 | 0.71 | CES1 (0.49) | CES1ESR2BCHEACHEPOLB | |
| SCHEMBL16143706 | 0.69 | CES1 (0.49) | CES1ESR2CES2KDM1AEED | |
| SCHEMBL29314362 | 0.68 | CES1 (0.55) | CES1ESR2BCHEACHECES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275707-A1 | SUBSTITUTED AFPO (6-ARYL-4H-FURO[3,2-C]PYRAN-4-ONE) DERIVATIVES AS ANTI-CANCER AGENTS | LEE KUO-HSIUNG | 2011-11-10 | — | — | US | disclosed |
| US-20110275707-A1 | SUBSTITUTED AFPO (6-ARYL-4H-FURO[3,2-C]PYRAN-4-ONE) DERIVATIVES AS ANTI-CANCER AGENTS | LEE KUO-HSIUNG | 2011-11-10 | — | — | US | disclosed |
| US-7795299-B2 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795299-B2 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-14 | — | — | US | disclosed |
| WO-2010080414-A2 | SUBSTITUTED FNO (2-[FURAN-2-YL] NAPHTHALEN-1-OL) DERIVATIVES AS ANTI-CANCER AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080415-A2 | SUBSTITUTED AFPO (6-ARYL-4H-FURO[3,2-C]PYRAN-4-ONE) DERIVATIVES AS ANTI-CANCER AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20090118356-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118356-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| US-7495026-B2 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070207989-A1 | DITERPENE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR, CANCER AND INFLAMMATORY DISEASES | SAVIPU PHARMACEUTICALS (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207989-A1 | DITERPENE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR, CANCER AND INFLAMMATORY DISEASES | NFKBIA, EDNRA, EDNRB | CES1 1756/4885ESR2 122/4885BCHE 4703/4885 |
| US-20110275707-A1 | SUBSTITUTED AFPO (6-ARYL-4H-FURO[3,2-C]PYRAN-4-ONE) DERIVATIVES AS ANTI-CANCER AGENTS | TP53, FOLR1, THPO | CES1 1786/4885ESR2 798/4885BCHE 4565/4885 |
| US-20090118356-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | BRCA1, CYP19A1, HUNK | CES1 2230/4885ESR2 28/4885BCHE 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.